Celebrating Dr. Rida Malik as Asundexian Receives FDA Approval

Celebrating our co-founder Dr. Rida Malik, a key contributor to asundexian research, following the medicine's FDA approval for secondary stroke prevention.

We're proud to celebrate our co-founder, Dr. Rida Malik, and a major milestone for research she helped advance. During her doctorate, Rida worked directly with Bayer as a key contributor to research on asundexian. On November 9, 2026, the FDA approved the medicine, now marketed as Sunharbo, for secondary stroke prevention.

FDA news release announcing approval of the first Factor XIa inhibitor to help prevent stroke in certain adults at high risk.
FDA announcement, November 9, 2026.

After years of scientific research, published findings, and extensive clinical trials, Sunharbo has become the first approved Factor XIa inhibitor. It is approved alongside antiplatelet therapy to reduce stroke risk in adults after a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA). Read the FDA announcement.

Years of research reaching patients

For our team, this is a deeply personal moment. Rida helped advance this research during her doctorate, and seeing that work connected to a medicine that can help improve people's lives is something worth celebrating.

We love seeing our team's work make a difference, both within AllMind and beyond it. This milestone gives us the chance to recognize Rida's contribution and the dedication behind years of scientific work.

Huge congratulations to Rida and everyone involved in making this possible!

Read more from our team: AllMind is now used at six Ivy League universities.